InvestorsHub Logo
Followers 6
Posts 538
Boards Moderated 0
Alias Born 06/06/2014

Re: None

Tuesday, 02/24/2015 10:39:52 AM

Tuesday, February 24, 2015 10:39:52 AM

Post# of 21507
Positive Phase 2a results (excerpt from 8-k)

Item 8.01 Other Events.
On February 24, 2015, Neurotrope, Inc. (the "Company") issued a press release (the "Press Release") regarding the top-line results from the Company's randomized, double-blind, placebo-controlled, single dose Phase 2a clinical trial evaluating bryostatin for the treatment of Alzheimer's disease. The Company announced that the Phase 2a safety study in nine Alzheimer's patients met its primary endpoint demonstrating preliminary safety and tolerability of bryostatin. The secondary objectives of the study, including, among others, the evaluation of the efficacy of a single dose of bryostatin in the treatment of patients with Alzheimer's disease, are still being reviewed.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News